Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing optimized, novel biologic treatments for inflammatory and immunology (I&I) conditions. The company's antibody programs aim to improve upon existing therapies by targeting established mechanisms of action and using advanced antibody engineering to enhance properties like half-life. Apogee's pipeline includes multiple antibody programs for I&I indications, both as monotherapies and combinations. Key product candidates include zumilokibart (APG777), APG279 (a combination of zumilokibart and APG990), APG273 (a combination of zumilokibart and APG333), and APG808. These programs are based on four validated targets. Zumilokibart (APG777) is a subcutaneous, extended half-life monoclonal antibody that targets IL-13. APG808 is a novel half-life extended IL-4Rα antibody. The company announced positive interim results from the Phase 1b trial of APG808 in patients with mild-to-moderate asthma in May 2025. Apogee is developing these treatments for conditions such as atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD), among other I&I indications. The agents listed are currently under investigation, and their safety and effectiveness have not yet been established by any regulatory authority.